Top Markets
Coin of the day
Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc.

LBPH
Rank in Stocks #8563
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Share Price
$59.98
Last synced: 2024-12-13
Market Cap
$1.22B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Longboard Pharmaceuticals, Inc. (LBPH)

Category

P/S ratio for Longboard Pharmaceuticals, Inc. (LBPH)
P/S ratio as of August 2026 TTM: 0.00
According to Longboard Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2022 the company had a P/S ratio of 0.00.
P/S ratio history for Longboard Pharmaceuticals, Inc. from 2020 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH